Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte Wildemann

Showing results (191-200 of 204) with videos related to

Pageof 21
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|December 27, 2024
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGADVivien Häußler, Corinna Trebst, Daniel Engels, et al.
Neurology|October 1, 2024
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European CohortMarius Ringelstein, Susanna Asseyer, Gero Lindenblatt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 27, 2016
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis opticaPatrick Waters, Markus Reindl, Albert Saiz, et al.
Annals of Neurology|December 12, 2023
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnkelien Duchow, Judith Bellmann-Strobl, Tim Friede, et al.
Journal of Neuroinflammation|January 21, 2012
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsSven Jarius, Klemens Ruprecht, Brigitte Wildemann, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 17, 2021
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum DisordersMarius Ringelstein, Ilya Ayzenberg, Gero Lindenblatt, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2020
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severityPatrick Ostkamp, Anke Salmen, Béatrice Pignolet, et al.
Genetic Epidemiology|October 27, 2015
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome ArrayTheresa Dankowski, Dorothea Buck, Till F M Andlauer, et al.
Ebiomedicine|August 1, 2025
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysisBrian C Zhang, Tilman Schneider-Hohendorf, Rebecca Elyanow, et al.
Frontiers in Immunology|April 28, 2025
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)Julian Reza Kretschmer, Daria Tkachenko, Tania Kümpfel, et al.
Pageof 21

Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
Journal of Neurology, Neurosurgery, and Psychiatry|December 27, 2024
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGADVivien Häußler, Corinna Trebst, Daniel Engels, et al.
Neurology|October 1, 2024
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European CohortMarius Ringelstein, Susanna Asseyer, Gero Lindenblatt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 27, 2016
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis opticaPatrick Waters, Markus Reindl, Albert Saiz, et al.
Annals of Neurology|December 12, 2023
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnkelien Duchow, Judith Bellmann-Strobl, Tim Friede, et al.
Journal of Neuroinflammation|January 21, 2012
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsSven Jarius, Klemens Ruprecht, Brigitte Wildemann, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 17, 2021
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum DisordersMarius Ringelstein, Ilya Ayzenberg, Gero Lindenblatt, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2020
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severityPatrick Ostkamp, Anke Salmen, Béatrice Pignolet, et al.
Genetic Epidemiology|October 27, 2015
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome ArrayTheresa Dankowski, Dorothea Buck, Till F M Andlauer, et al.
Ebiomedicine|August 1, 2025
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysisBrian C Zhang, Tilman Schneider-Hohendorf, Rebecca Elyanow, et al.
Frontiers in Immunology|April 28, 2025
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)Julian Reza Kretschmer, Daria Tkachenko, Tania Kümpfel, et al.
Pageof 21